Vortex keratopathy associated with atovaquone.
OBJECTIVE
We studied a case of vortex keratopathy that was associated with the use of atovaquone.


METHODS
A patient with acquired immunodeficiency syndrome (AIDS) with pulmonary Pneumocystis carinii was treated with 750 mg of atovaquone three times a day.


RESULTS
Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties. This property is similar to that of other lipophilic agents such as amiodarone, chloroquine, chlorpromazine, quinacrine, and suramin.


CONCLUSIONS
Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D053626:Atovaquone; D003315:Cornea / Q000187:drug effects* / Q000473:pathology; D003316:Corneal Diseases / Q000139:chemically induced* / Q000473:pathology; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009285:Naphthoquinones / Q000009:adverse effects* / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy
D000935:Antifungal Agents; D009285:Naphthoquinones; D053626:Atovaquone